Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
First human trial of cellular rejuvenation therapy begins after two decades of research

First human trial of cellular rejuvenation therapy begins after two decades of research

New Capabilities

Life Biosciences tests whether partially resetting the epigenetic clock can restore vision in glaucoma patients

April 9th, 2026: Nature highlights first human cellular rejuvenation trial

Overview

In 2006, Shinya Yamanaka showed that four genes could rewind an adult cell all the way back to an embryonic-like state. Twenty years later, a stripped-down version of that technique is being injected into human eyes for the first time. Life Biosciences, a Boston biotech co-founded by Harvard aging researcher David Sinclair, has begun dosing glaucoma patients with ER-100, a gene therapy that delivers three of Yamanaka's four reprogramming factors to retinal cells — with a built-in off switch controlled by the common antibiotic doxycycline.

The Phase 1 trial, cleared by the Food and Drug Administration (FDA) in January 2026 and featured in Nature's April 9 issue, tests whether partially dialing back a cell's biological clock can restore function in damaged human tissue without triggering dangerous side effects like tumor growth. If the therapy works, it would validate a radically new approach to medicine: not just treating disease, but reversing the cellular aging that causes it. Billions of dollars and a new generation of biotech companies are riding on the answer.

Why it matters

If resetting a cell's age can restore lost vision, the same approach could eventually target heart disease, neurodegeneration, and aging itself.

Play on this story Voices Debate Predict

Key Indicators

1st
First human trial of epigenetic reprogramming
ER-100 is the first cellular rejuvenation therapy to receive FDA clearance for testing in humans.
3
Yamanaka factors used (of four)
The fourth factor, c-Myc, was excluded because it is associated with cancer.
$80M
Series D funding closed April 8, 2026
Funds the trial through completion and advances Life Biosciences' broader reprogramming platform.
20 years
From discovery to human trial
Yamanaka published the foundational induced pluripotent stem cell research in 2006.
$6B+
Estimated capital invested across reprogramming field
Altos Labs alone launched with roughly $3 billion; dozens of startups have raised additional billions.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

David A. Sinclair
David A. Sinclair
Leading the scientific vision behind the first human reprogramming trial
 Jerry McLaughlin
Jerry McLaughlin
Leading company through its first clinical trial and $80M Series D raise
 Shinya Yamanaka
Shinya Yamanaka
Director Emeritus, Center for iPS Cell Research and Application (CiRA), Kyoto University; Senior Investigator, Gladstone Institutes

Organizations Involved

Life Biosciences
Life Biosciences
Clinical-stage biotechnology company
Conducting the first-ever human trial of cellular rejuvenation therapy

Boston-based biotech developing partial epigenetic reprogramming therapies to reverse aging-related diseases.
Altos Labs
Altos Labs
Biotechnology research company
Began early human safety testing in August 2025; transitioning toward clinical stage

The best-funded company in cellular reprogramming, backed by roughly $3 billion from investors including Jeff Bezos and Yuri Milner.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Cleared the first human trial of epigenetic reprogramming therapy

The United States agency responsible for approving drugs, biologics, and gene therapies for human use.

Timeline

  1. Nature highlights first human cellular rejuvenation trial

    Publication

    Nature's April 9 issue features the launch of the ER-100 trial as a landmark moment for longevity medicine, with accompanying analysis in Nature Biotechnology examining the science and regulatory significance.

  2. Life Biosciences closes $80 million Series D

    Corporate

    Life Biosciences closes a fully subscribed $80 million Series D round to fund the ER-100 trial through completion and advance its broader reprogramming platform into additional indications.

  3. FDA clears first human trial of cellular rejuvenation

    Regulatory

    The FDA clears Life Biosciences' Investigational New Drug application for ER-100, making it the first epigenetic reprogramming therapy authorized for testing in humans. The Phase 1 trial will enroll patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

  4. Life Biosciences presents preclinical data at ARDD 2025

    Scientific Presentation

    Life Biosciences presents new data on its Partial Epigenetic Reprogramming platform in liver and ocular diseases at the Aging Research and Drug Discovery conference.

  5. Sinclair publishes epigenetic information theory of aging

    Scientific Discovery

    Sinclair's lab publishes in Cell providing evidence that aging is driven by the loss of epigenetic information, not just genetic mutations, and that this process is reversible.

  6. Altos Labs launches with $3 billion

    Corporate

    Altos Labs launches as the best-funded company in the reprogramming field, backed by Jeff Bezos and Yuri Milner, recruiting top scientists including Yamanaka as an advisor.

  7. Sinclair lab restores vision in blind mice via epigenetic reprogramming

    Scientific Discovery

    David Sinclair's lab publishes in Nature showing that delivering three Yamanaka factors (Oct4, Sox2, Klf4) to retinal ganglion cells reverses vision loss in mice with glaucoma and in aged mice — the foundational proof-of-concept for ER-100.

  8. FDA approves Luxturna, first ocular gene therapy

    Regulatory

    The FDA approves Spark Therapeutics' Luxturna (voretigene neparvovec) for inherited retinal dystrophy, establishing a regulatory precedent for delivering gene therapies directly into the eye.

  9. Life Biosciences founded

    Corporate

    David Sinclair co-founds Life Biosciences in Boston to develop therapies targeting the mechanisms of aging, initially as a holding company with multiple subsidiaries.

  10. First in vivo partial reprogramming extends lifespan in mice

    Scientific Discovery

    Juan Carlos Izpisua Belmonte's lab at the Salk Institute publishes in Cell showing that cyclic, short-term expression of Yamanaka factors extends lifespan in a mouse model of premature aging — the first proof that partial reprogramming works in living animals.

  11. Yamanaka awarded Nobel Prize

    Recognition

    Shinya Yamanaka and Sir John Gurdon share the Nobel Prize in Physiology or Medicine for demonstrating that mature cells can be reprogrammed to a pluripotent state.

  12. Yamanaka publishes iPSC discovery

    Scientific Discovery

    Shinya Yamanaka and Kazutoshi Takahashi publish in Cell showing that four genes — Oct4, Sox2, Klf4, and c-Myc — can reprogram adult mouse cells into an embryonic-like pluripotent state.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

ER-100 proves safe, shows early signs of restoring vision

The Phase 1 trial completes with no serious adverse events, and some patients show measurable improvements in visual function. This would validate partial epigenetic reprogramming as a viable therapeutic approach and trigger a Phase 2 trial with a larger patient group. It would also catalyze clinical programs across the rejuvenation field, including at Altos Labs and Retro Biosciences, and likely drive a surge in investment.

Discussed by: Nature Biotechnology, MIT Technology Review, longevity research community
Consensus —
2

Trial demonstrates safety but no measurable efficacy

ER-100 proves safe in the small Phase 1 cohort, but the reprogramming effect is too weak or too transient to produce detectable vision improvement. This would not kill the field — Phase 1 trials prioritize safety — but would raise questions about dosing, delivery duration, and whether the mouse-to-human translation gap is larger than hoped. Life Biosciences would need to optimize the therapy before proceeding.

Discussed by: Fight Aging!, skeptical researchers including Paul Knoepfler
Consensus —
3

Serious safety signal halts the trial

The doxycycline control mechanism fails to prevent over-reprogramming in one or more patients, leading to abnormal cell growth, immune reactions, or other serious adverse events. The trial is paused or terminated, triggering regulatory scrutiny of the entire reprogramming field. This echoes the 1999 Jesse Gelsinger case, which set gene therapy back by a decade. The eye's confined anatomy limits worst-case scenarios, but any safety failure in this closely watched trial would have outsized consequences.

Discussed by: Bioethicists, gene therapy safety researchers, Nature Biotechnology risk analysis
Consensus —
4

Competing approaches reach clinical trials, fragmenting the field

Altos Labs, which reportedly began early human safety testing in 2025, advances its own reprogramming therapy into formal clinical trials. Turn Biotechnologies advances its messenger RNA-based approach, which avoids permanent genetic modification entirely. Multiple competing methods enter human testing within 12 to 18 months, creating a crowded clinical landscape where different delivery systems, factor combinations, and target tissues are tested simultaneously.

Discussed by: Longevity Technology, Labiotech, industry analysts
Consensus —

Historical Context

Luxturna: First ocular gene therapy (2017)

December 2017

What Happened

Spark Therapeutics won FDA approval for Luxturna (voretigene neparvovec), a gene therapy injected directly into the eye to treat an inherited form of blindness caused by mutations in the RPE65 gene. In the pivotal trial, 27 of 29 patients experienced improved sight. The advisory committee voted 16-0 in favor of approval.

Outcome

Short Term

Luxturna launched at a price of $850,000 per patient, sparking debate about gene therapy pricing. It demonstrated that the eye is a viable and relatively safe compartment for gene therapy delivery.

Long Term

Luxturna established the regulatory template for ocular gene therapies, creating the pathway that Life Biosciences followed to get ER-100 into human trials. It proved that a single injection could produce lasting therapeutic benefit in a confined organ.

Why It's Relevant Today

ER-100 uses the same basic delivery approach — an adeno-associated virus injected into the eye — and benefits directly from the safety and regulatory precedent Luxturna established. The eye's immune-privileged status and small volume make it the safest starting point for a novel gene therapy.

Jesse Gelsinger gene therapy death (1999)

September 1999

What Happened

Jesse Gelsinger, an 18-year-old with a mild liver disorder called ornithine transcarbamylase deficiency, died four days after receiving an experimental adenoviral gene therapy at the University of Pennsylvania. His immune system mounted an overwhelming inflammatory response to the viral vector. Investigations revealed undisclosed safety problems in earlier patients and conflicts of interest among the researchers.

Outcome

Short Term

The FDA halted multiple gene therapy trials nationwide. The principal investigator, James Wilson, was barred from conducting FDA-regulated research for five years. Public trust in gene therapy collapsed.

Long Term

The field pivoted to safer adeno-associated virus (AAV) vectors instead of adenoviruses, developed more rigorous safety monitoring protocols, and took nearly two decades to recover. The caution instilled by this case shaped every subsequent gene therapy trial design, including ER-100's.

Why It's Relevant Today

The Gelsinger case is the cautionary backdrop for every first-in-human gene therapy trial. Life Biosciences' decision to target the eye — a small, enclosed organ where damage stays localized — and to include a doxycycline safety switch reflects lessons learned from this tragedy. Any serious adverse event in the ER-100 trial would be measured against this precedent.

CRISPR gene editing reaches the clinic (2019-2023)

2019-2023

What Happened

The first CRISPR-based gene editing therapy entered human trials in 2019. After four years of clinical testing, the FDA approved Casgevy (exagamglogene autotemcel) in December 2023 for sickle cell disease — the first CRISPR therapy to receive regulatory approval anywhere. The arc from Emmanuelle Charpentier and Jennifer Doudna's foundational 2012 paper to approval took 11 years.

Outcome

Short Term

Casgevy's approval validated CRISPR as a clinical tool and opened a wave of gene editing therapies for blood disorders, cancer, and inherited diseases.

Long Term

CRISPR therapies are now in dozens of clinical trials across multiple disease areas, with the technology becoming increasingly precise and versatile.

Why It's Relevant Today

The CRISPR arc — from Nobel-winning basic science to clinical approval in roughly a decade — offers the most direct parallel for where epigenetic reprogramming stands today. Life Biosciences' ER-100 trial is the equivalent of CRISPR's first human tests: the moment a transformative laboratory technique begins proving itself in patients.

Sources

(11)
+5
Nature Life Biosciences MIT Technology Review Fortune BioSpace ClinicalTrials.gov Lifespan.io Longevity Technology Nature Biotechnology Nature Nature